Rechte & Gesellschaft
EMA Restricts Use of Tecovirimat SIGA
The European Medicines Agency (EMA) has recommended restricting the use of Tecovirimat SIGA, a medication previously authorized for treating mpox. The EMA's committee for human medicines (CHMP) advised against its continued use for mpox treatment, citing updated clinical data. This recommendation does not impact the drug's authorized use for other conditions, such as smallpox and cowpox. The EMA's decision reflects its commitment to ensuring the safety and effectiveness of medicines available in the EU.
Mpox treatment faces restriction due to updated clinical data.